My posts will be on Substack and I will share excerpts of my book through linkposts.

I'm working on a book that discusses the economics of innovation and changemaking because even philanthropic endeavors need to assess the flow of money to be viable. This excerpt discusses the antibiotic market.

Because the society has to limit the use of new antibiotics in order to avoid the rise of antibiotics resistance to them (keeping them as “weapons of last resort”), the side effect of that is that the creators of new antibiotics don’t make any meaningful money and only suffer financial losses from those undertakings.

So pharma stopped developing new antibiotics.